Skip to content

A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Variant-Adapted BNT162b2 RNA-Based Vaccine Candidate(s) in Health Children (Pfizer C4591048)

Nicola Klein | Industry Ongoing

Explore all studies

Back To Top